Efficacy and Safety of Low-dose Ticagrelor

Efficacy and Safety of Different Ticagrelor Regimens Versus Clopidogrel in Patients With Coronary Artery Disease: a Retrospective Multicenter Study (SUPERIOR)

Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary heart disease.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Disease
• Intervention / Treatment: Drug: Ticagrelor; Drug: ticagrelor; Drug: ticagrelor; Drug: clopidogrel

Detailed Description

Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine diphosphate (ADP) receptor.

Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg daily plus aspirin for ACS patients. Recent study found that ticagrelor 90mg twice a day orally could significantly reduce the occurrence of clopidogrel resistance and adverse cardiovascular events. The previous studies have reported that half-dose ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose clopidogrel in Chinese patients with stable CAD. But large-scale clinical trials are still needed to confirm the effects of low-dose ticagrelor on platelet function in Chinese patients with coronary heart disease.

• Study Type: Interventional
• Enrollment (Actual): 3043
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• China
  • Beijing, China, 100001
    • Thromboela-Stogram

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with coronary artery disease

Exclusion Criteria:

• younger than 18 years of age;
• anti-platelet therapy with clopidogrel or ticagrelor for less than 5 days;
• previous or current treatment with any other potentially confounding drugs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ticagrelor 45mg bidpo.; To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.	Drug: Ticagrelor; ticagrelor 45 mg twice daily for 5 consecutive days at least.
Experimental: ticagrelor 90mg qdpo.; To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.	Drug: ticagrelor; ticagrelor 90 mg once daily for 5 consecutive days at least.; Drug: ticagrelor; ticagrelor 90 mg twice daily for 5 consecutive days at least.
Active Comparator: ticagrelor 90mg bidpo.; To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.	Drug: ticagrelor; ticagrelor 90 mg once daily for 5 consecutive days at least.; Drug: ticagrelor; ticagrelor 90 mg twice daily for 5 consecutive days at least.
Active Comparator: clopidogrel 75mg qdpo.; To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.	Drug: clopidogrel; clopidogrel 75 mg once daily for 5 consecutive days at least.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ADP-induced Inhibition of Platelet Aggregation	The venous blood samples for platelet function test were drawn after an overnight fast, at 12 hours post-last study-drug dose for subjects receiving twice-daily administrations, and at 24 hours post-last study-drug dose for subjects treated with once-daily regimens. The blood was collected in an evacuated vacuum tube containing 3.2% trisodium citrate and lithium heparin. Then the samples were processed within two hours of blood draw according to standard operating procedure. The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced inhibition of platelet aggregation (IPA, range 0% - 100%), with higher values indicating greater platelet inhibition.	up to 5 days
Number of Participants With Bleeding (Major or Minor Bleeding)	Major bleeding was defined as type ≥ 3 and minor bleeding as types 1 and 2, in accordance to the Bleeding Academic Research Consortium classification. (Mehran R et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.)	up to 5 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
ADP-induced Platelet-fibrin Clot Strength (MA)	The physical properties of samples were analyzed using Thromboelastography (TEG) Hemostasis Analyzer (CFMS LEPU-8800, Lepu Medical Technology Co., Ltd, Beijing, China) and automated analytical software. TEG test used four channels to detect the effects of anti-platelet therapy via the arachidonic acid (AA) and ADP pathways. TEG test results were expressed in terms of ADP-induced platelet-fibrin clot strength (MA). A MA>47mm was shown to have a high predictive value for 3-year post-PCI ischemic events during dual antiplatelet therapy. Moreover, ROC curve and quartile analysis suggested MA<31 mm as a predictive value for post-PCI bleeding events (J Am Coll Cardiol. 2013;62(24):2261-73. doi: 10.1016/j.jacc.2013.07.101.).	up to 5 days
Number of Participants With High On-Treatment Platelet Reactivity (HTPR)	HTPR was defined as IPA ≤ 30% and MA ≥ 47 mm.	up to 5 days
Number of Participants With Cardiovascular Event (Cardiovascular Death, New-onset Myocardial Infarction, or Stroke)	Cardiovascular death was defined as sudden cardiac death, fatal myocardial infarction, death due to heart failure, or death due to other cardiovascular causes. Stroke was defined as the focal loss of neurologic function caused by an ischemic or a hemorrhagic event with residual symptoms lasting at least 24 hours or eventually leading to death.	up to 5 days
Number of Participants With New-onset Dyspnea	New-onset dyspnea in patients without previous history of dyspnea	up to 5 days

Collaborators and Investigators

• Sponsor: First Affiliated Hospital of Harbin Medical University
• Collaborators: RenJi Hospital; Shengjing Hospital; Beijing Anzhen Hospital; Shaanxi Provincial People's Hospital; Wuhan Union Hospital, China; Tianjin Medical University General Hospital; The First Affiliated Hospital of Kunming Medical College; The First Affiliated Hospital of Dalian Medical University; Weifang People's Hospital; The Central Hospital of Jia Mu Si City
• Investigators: Principal Investigator: Yue Li, MD, Cardiovascular Department, the First Affiliated Hospital of Harbin Medical University

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2017
• Primary Completion (Actual): December 13, 2018
• Study Completion (Actual): February 13, 2019

Study Registration Dates

• First Submitted: December 14, 2017
• First Submitted That Met QC Criteria: December 20, 2017
• First Posted (Actual): December 22, 2017

Study Record Updates

• Last Update Posted (Actual): September 30, 2019
• Last Update Submitted That Met QC Criteria: August 28, 2019
• Last Verified: June 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Coronary Artery Disease; Myocardial Ischemia; Coronary Disease; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Ticagrelor; Clopidogrel
• Other Study ID Numbers: ACS-2

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No